Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Aug;16(4):429-432.
doi: 10.1007/s40258-018-0393-7.

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson  1 , Angela Boland  2 , Rui Duarte  2 , Eleanor Kotas  2 , Nerys Woolacott  3 , Robert Hodgson  3 , Rob Riemsma  4 , Sabine Grimm  5 , Bram Ramaekers  5 , Manuela Joore  5 , Nasuh Büyükkaramikli  6 , Eva Kaltenthaler  7 , Matt Stevenson  7 , Abdullah Pandor  7 , Steve Edwards  8 , Martin Hoyle  9 , Jonathan Shepherd  10 , Xavier Armoiry  11 , Miriam Brazzelli  12
Affiliations
Editorial

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Rumona Dickson et al. Appl Health Econ Health Policy. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Rumona Dickson, Angela Boland, Rui Duarte, Eleanor Kotas, Nerys Woolacott, Robert Hodgson, Rob Riemsma, Sabine Grimm, Bram Ramaekers, Manuela Joore, Nasuh Büyükkaramikli, Eva Kaltenthaler, Matt Stevenson, Abdullah Pandor, Steve Edwards, Martin Hoyle, Jonathan Shepherd, Xavier Armoiry and Miriam Brazzelli have no competing interests.

Funding

The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA Programme. The views and opinions expressed are those of the authors and do not necessarily reflect those of the UK Department of Health and the NIHR.

References

    1. European Medicines Agency. Pharmacovigilance: post authorisation 2018 [updated 2016; cited 2018 01 March]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/gen....
    1. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ. 2017;359:j4530. doi: 10.1136/bmj.j4530. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence. Technology appraisal guidance 2018. https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-guidance/NI....
    1. McCabe C, Paul A, Fell G, Paulden M. Cancer Drugs Fund 2.0: a missed opportunity? PharmacoEconomics. 2016;34(7):629–633. doi: 10.1007/s40273-016-0403-2. - DOI - PubMed
    1. National Institute for Health and Care Excellence. Find NICE guidance 2018. https://www.nice.org.uk/guidance.

Publication types

MeSH terms

Substances